neuro42

Executive Summary

neuro42 is a San Francisco-based medical technology company developing a portable, low-field MRI platform integrated with AI and robotics for neurosurgical guidance. Founded in 2021, the company aims to transform neurological care by bringing advanced imaging directly to the point of care, enabling real-time diagnosis and intervention. Its FDA 510(k)-cleared system is designed to improve patient comfort, procedural precision, and workflow efficiency in settings like operating rooms and ICUs. By combining low-field MRI with AI-powered image reconstruction and robotic assistance, neuro42 addresses key limitations of traditional high-field MRI, including high cost, large footprint, and immobility, potentially expanding access to critical imaging in emergency and surgical settings. The market opportunity for portable, point-of-care MRI is substantial, driven by the need for rapid, accurate neuroimaging in stroke, trauma, and intraoperative guidance. neuro42 differentiates itself through its integrated AI and robotics, offering a solution that can be deployed outside radiology suites. While still early-stage with limited public financial or clinical data, the company's FDA clearance provides a regulatory foundation for commercialization. Future success will depend on clinical adoption, reimbursement, and competitive positioning against emerging portable MRI systems. Key catalysts include additional regulatory clearances, clinical validation studies, strategic partnerships, and funding rounds to support commercial scale-up.

Upcoming Catalysts (preview)

• Q4 2026Expanded FDA 510(k) Clearance for Intraoperative Indications70% success
• Q2 2026Series A Funding Round80% success
• Q3 2026Strategic Partnership with a Major Hospital System or Surgical Robotics Company60% success